Status:

COMPLETED

Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin

Lead Sponsor:

Henry Ford Health System

Collaborating Sponsors:

Beckman Coulter, Inc.

Conditions:

Chest Pain

Myocardial Ischemia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

As part of the planned implementation of a new clinical pathway using hs-cTnI, the investigators will measure patient outcomes and clinical processes in a real-world scenario throughout an integrated ...

Detailed Description

This is a pragmatic, implementation study testing the implications of a real-world execution of a rapid evaluation pathway for suspected ACS using the Beckman hs-cTnI assay. As the new protocol is exe...

Eligibility Criteria

Inclusion

  • Patients ≥18 years old presenting to the ED for whom a treating clinician suspects ACS and orders a baseline ECG and cardiac troponin.

Exclusion

  • ST-segment Myocardial Infarction (STEMI) leading to immediate reperfusion therapy
  • Any ED-drawn hs-cTnI value \> 99th percentile (18 ng/L)
  • Clear traumatic cause for symptoms (e.g., direct chest wall trauma, motor vehicle accident)
  • A transfer from another facility
  • Primary residence outside the state of Michigan
  • Previous inclusion in the study
  • Enrolled in hospice

Key Trial Info

Start Date :

July 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 3 2022

Estimated Enrollment :

32609 Patients enrolled

Trial Details

Trial ID

NCT04488913

Start Date

July 29 2020

End Date

March 3 2022

Last Update

March 23 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Henry Ford Health System

Detroit, Michigan, United States, 48202